The effect of pirozadil on plasma lipids and lipoproteins in 1185 hyperlipidaemic subjects. Multicentre study in general practice in Spain.
The lipid-lowering agent pirozadil was tested in 1185 hyperlipidaemic subjects during a 2-4 months' intake. Plasma triglycerides were found to decrease by 30.8%. The reduction of plasma cholesterol (by 20.8%) was mainly due to a fall in low-density lipoprotein cholesterol by 23.7%, while high-density lipoprotein cholesterol increased up to 32.2%. Pirozadil was effective and well-tolerated in patients with both hypercholesterolaemia and hypertriglyceridaemia.